secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045904
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics Q3 revenue up 17% to $3.9M; operating loss down 27%; FDA clearance for pediatric OSA
--------------------------------------------------------------------------------

- Q3 2024 revenue $3.9M (+17% YoY); gross margin improved to 60% from 53%.
- Operating loss decreased $1M (27%) YoY; operating expenses down 8% — ninth consecutive quarter of reduction.
- Cash and equivalents $6.3M, stockholders' equity $7.7M; raised $4.3M via registered direct equity offering in Sept.
- First FDA 510(k) clearance for treating moderate-to-severe OSA in children 6-17; AMA CPT codes for Vivos devices effective Jan 1, 2025.
- Over 47,000 patients treated globally; new marketing model expanding to two more Colorado locations by early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224045904/0001493152-24-045904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224045904/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer